Core Insights - The China International Import Expo (CIIE) has become a significant platform for accelerating the availability of innovative drugs to Chinese patients, as highlighted by Novartis and Gilead Sciences [1][2] Group 1: Novartis - Novartis has showcased its innovative cardiovascular and renal treatment solutions at the CIIE, marking its eighth consecutive year of participation [1] - Several innovative drugs in the cardiovascular and renal fields have transitioned from exhibition to approval, benefiting from the spillover effects of the CIIE [1] Group 2: Gilead Sciences - Gilead Sciences has introduced two products at the CIIE, including the long-acting HIV prevention drug Lenacapavir and a new drug for primary biliary cholangitis, marking their Asian debut [1] - The company is actively advancing local R&D with 16 ongoing projects in China, including 10 in oncology and 6 in non-oncology, aiming for 90% of oncology projects to achieve global synchronization [2] - Gilead plans to sign nearly ten cooperation projects at the CIIE to enhance the accessibility of innovative drugs and promote standardized diagnosis and treatment [3]